Organon Follistim male infertility approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Organon's Follistim (follitropin beta) adds indication Feb. 7 for induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure. Follistim was previously approved for fertility treatment in women. Serono's Gonal-F was the first gonadotropin to receive the spermatogenesis indication, in May 200